Alterity Therapeutics Limited (PRNAF)
OTCMKTS · Delayed Price · Currency is USD
0.0030
-0.0109 (-78.42%)
At close: Jun 16, 2025
Alterity Therapeutics Revenue
In the fiscal year ending June 30, 2025, Alterity Therapeutics had annual revenue of 5.44M AUD with 35.32% growth. Alterity Therapeutics had revenue of 3.83M in the half year ending June 30, 2025, with 150.44% growth.
Revenue
5.44M AUD
Revenue Growth
+35.32%
P/S Ratio
22.20
Revenue / Employee
604.32K AUD
Employees
9
Market Cap
79.15M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2025 | 5.44M | 1.42M | 35.32% |
Jun 30, 2024 | 4.02M | 102.95K | 2.63% |
Jun 30, 2023 | 3.92M | -1.21M | -23.56% |
Jun 30, 2022 | 5.12M | 783.93K | 18.06% |
Jun 30, 2021 | 4.34M | - | - |
Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Tian'an Technology Group | 2.12M |
Elite Pharmaceuticals | 105.45M |
Glass House Brands | 221.55M |
Northwest Biotherapeutics | 1.09M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
AMJ Global Technology | 39.00 |
Alterity Therapeutics News
- 3 days ago - Alterity Therapeutics (ATHE) Reports Promising Phase 2 Trial Results for ATH434 - GuruFocus
- 10 days ago - Alterity Therapeutics (ATHE) Secures A$20M in New Funding - GuruFocus
- 10 days ago - Alterity Therapeutics raises A$20 million in strategic placement - Seeking Alpha
- 10 days ago - Alterity Therapeutics Raises A$20.0 million in Strategic Placement - GlobeNewsWire
- 16 days ago - Alterity Therapeutics to Present at the Biotech Showcase - GlobeNewsWire
- 7 weeks ago - Appendix 4C – Q4 FY25 Quarterly Cash Flow Report - GlobeNewsWire
- 7 weeks ago - Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy - GlobeNewsWire
- 2 months ago - Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study - GlobeNewsWire